Watch Demo

Age-related Macular Degeneration Market Research Report by Type, Treatment Type, Distribution Channel, Country - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - North America Forecast 2023-2030

Age-related Macular Degeneration Market Research Report by Type, Treatment Type, Distribution Channel, Country - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - North America Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:141

  • Report ID:6384536

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Age-related Macular Degeneration Market Research Report by Type (Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration), Treatment Type, Distribution Channel, Country - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - North America Forecast 2023-2030

The North America Age-related Macular Degeneration Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the North America Age-related Macular Degeneration Market.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the North America Age-related Macular Degeneration Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the North America Age-related Macular Degeneration Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The North America Age-related Macular Degeneration Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the North America Age-related Macular Degeneration Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the North America Age-related Macular Degeneration Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market is studied across Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration.

Based on Treatment Type, the market is studied across Drugs and Laser Treatment.

Based on Distribution Channel, the market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on Country, the market is studied across Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the North America Age-related Macular Degeneration Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The North America Age-related Macular Degeneration Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The North America Age-related Macular Degeneration Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The North America Age-related Macular Degeneration Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the North America Age-related Macular Degeneration Market, including Alkahest, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Annexon, Inc., Apellis Pharmaceuticals, Inc., Bayer AG, CellCure Neurosciences by BioTime, Inc., Clearside Biomedical, Inc., Gemini Therapeutics, Inc., Graybug Vision, Inc., Gyroscope Therapeutics Limited by Novartis AG, Heidelberg Engineering GmbH, Ionis Pharmaceuticals, Inc., Kodiak Sciences Inc., and Santen Pharmaceutical Co., Ltd..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the North America Age-related Macular Degeneration Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the North America Age-related Macular Degeneration Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the North America Age-related Macular Degeneration Market?
4. What is the competitive strategic window for opportunities in the North America Age-related Macular Degeneration Market?
5. What are the technology trends and regulatory frameworks in the North America Age-related Macular Degeneration Market?
6. What is the market share of the leading vendors in the North America Age-related Macular Degeneration Market?
7. What modes and strategic moves are considered suitable for entering the North America Age-related Macular Degeneration Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Age-related Macular Degeneration Market, by Type
6.1. Introduction
6.2. Dry Age-Related Macular Degeneration
6.3. Wet Age-Related Macular Degeneration

7. Age-related Macular Degeneration Market, by Treatment Type
7.1. Introduction
7.2. Drugs
7.3. Laser Treatment

8. Age-related Macular Degeneration Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies

9. Canada Age-related Macular Degeneration Market
9.1. Introduction

10. Mexico Age-related Macular Degeneration Market
10.1. Introduction

11. United States Age-related Macular Degeneration Market
11.1. Introduction

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Alkahest, Inc.
13.2. Alkeus Pharmaceuticals, Inc.
13.3. Allegro Ophthalmics, LLC
13.4. Annexon, Inc.
13.5. Apellis Pharmaceuticals, Inc.
13.6. Bayer AG
13.7. CellCure Neurosciences by BioTime, Inc.
13.8. Clearside Biomedical, Inc.
13.9. Gemini Therapeutics, Inc.
13.10. Graybug Vision, Inc.
13.11. Gyroscope Therapeutics Limited by Novartis AG
13.12. Heidelberg Engineering GmbH
13.13. Ionis Pharmaceuticals, Inc.
13.14. Kodiak Sciences Inc.
13.15. Santen Pharmaceutical Co., Ltd.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET: RESEARCH PROCESS
FIGURE 2. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2022 VS 2030
FIGURE 3. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 5. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 7. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET DYNAMICS
FIGURE 8. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 10. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2030
FIGURE 12. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
FIGURE 13. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
FIGURE 14. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2022 VS 2030 (%)
FIGURE 15. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET COMPETITIVE STRATEGIC WINDOW, BY TREATMENT TYPE, 2030
FIGURE 17. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
FIGURE 18. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
FIGURE 19. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 20. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2030
FIGURE 22. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
FIGURE 23. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
FIGURE 24. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
FIGURE 25. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 26. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 27. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 28. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 29. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 30. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 31. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 32. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 33. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 5. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 7. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 8. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 9. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 10. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 11. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 12. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 13. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
TABLE 14. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER TREATMENT, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 15. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 16. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 17. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 18. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 19. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 21. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 23. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 25. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 27. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 29. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 36. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 37. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 38. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET RANKING, BY KEY PLAYER, 2022
TABLE 39. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2022
TABLE 40. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 41. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET MERGER & ACQUISITION
TABLE 42. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 43. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 44. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET INVESTMENT & FUNDING
TABLE 45. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 46. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET: LICENSE & PRICING

Companies Mentioned

Alkahest, Inc.
Alkeus Pharmaceuticals, Inc.
Allegro Ophthalmics, LLC
Annexon, Inc.
Apellis Pharmaceuticals, Inc.
Bayer AG
CellCure Neurosciences by BioTime, Inc.
Clearside Biomedical, Inc.
Gemini Therapeutics, Inc.
Graybug Vision, Inc.
Gyroscope Therapeutics Limited by Novartis AG
Heidelberg Engineering GmbH
Ionis Pharmaceuticals, Inc.
Kodiak Sciences Inc.
Santen Pharmaceutical Co., Ltd.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.